Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases
CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit (PPU). The first goal is to go after hard to treat solid tumors.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.